Australian researchers have identified a new molecule that has the capacity to ‘calm’ the immune system in mice with type 1 diabetes.
This study showed that the molecule, known as CD52, is released by a specific sub-set of T-cells in the immune system. CD52 attaches itself to a ‘receptor’ and starts a chain of molecule-based events. This led to a calming effect on immune cells that were attacking ‘self’ proteins.
The study also showed that levels of CD52 are lower in people with type 1 diabetes. Furthermore, the study showed that the onset of type 1 diabetes in diabetic mice was associated with a reduced level of CD52.
Moving forward, the ability of CD52 to calm the immune system during type 1 diabetes has the potential as both a preventative therapy and a treatment in controlling the immune system and immune attack. Further studies to validate the safety and effectiveness of CD25 are needed.